Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.
Catherine ThieblemontTycel Jovelle PhillipsHervé GhesquièresChan Yoon Y CheahMichael Roost ClausenDavid CunninghamYoung Rok DoTatyana FeldmanRobin GasiorowskiWojciech JurczakTae Min KimDavid John LewisMarjolein van der PoelMichelle Limei PoonMariana Cota StirnerNurgul KilavuzChristopher ChiuMenghui ChenMariana SacchiBrian ElliottTahamtan AhmadiMartin HutchingsPieternella J LugtenburgPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Subcutaneous epcoritamab resulted in deep and durable responses and manageable safety in highly refractory patients with large B-cell lymphoma, including those with prior CAR T-cell exposure.